Hearing on Barriers to Medical Innovation and Patient Access
January 1, 2024
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
The Frame
This hearing signals potential legislative efforts to limit 's ability to restrict coverage for new FDA-approved drugs, which could change how quickly patients gain access to emerging medical treatments and how Medicare funds those drugs.
Potentially affected actors named in the source documents. Mention is not a position.
Medicare patients
Changes to CMS coverage policies directly impact the availability and cost of new medical treatments for these individuals.
Pharmaceutical companies
Federal policies on drug price negotiation and coverage mandates affect the marketability and revenue potential of new drugs.
Last recorded activity January 1, 2024.
Next step not available in the current record.
Summary
Key Facts
- The Subcommittee on Health held a hearing on May 10, 2023, to discuss policies affecting medical innovation and patient access.
- Chairman Buchanan introduced the MERIT Act, which would require CMS to evaluate new drugs on an individual basis rather than as a class.
- The hearing addressed CMS's restrictive coverage policies for Alzheimer's treatments.
- 26 state attorneys general sent a letter to Secretary Becerra requesting CMS coverage for certain Alzheimer's drugs.
- The committee discussed the impact of the Inflation Reduction Act's drug price negotiation provisions.
- The hearing examined the USTR's TRIPS waiver regarding intellectual property protections for COVID-19 vaccines.
- The committee reviewed CMMI's potential changes to coverage for Part B drugs that receive FDA accelerated approval.
Frequently Asked Questions
What is the MERIT Act?
Why are some members of Congress concerned about CMS coverage?
Why It Matters
This hearing signals potential legislative efforts to limit 's ability to restrict coverage for new FDA-approved drugs, which could change how quickly patients gain access to emerging medical treatments and how Medicare funds those drugs.
News Coverage
Sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
CMS Coverage Strategy
The hearing highlights a clear legislative push to restrict CMS's ability to use 'class-based' coverage denials for new drugs.
Connected Entities
Sources
www.govinfo.gov
Analysis Score
0–100- Significance75How much this matters to a regular citizen
- Controversy65Intensity of disagreement among stakeholders
- Entertainment20Compellingness for a non-policy-wonk reader
- Buzz30Current news / social attention level
Publisher tools